Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …

Importance Approximately 90% of people in the US experience headache during their
lifetime. Migraine is the second leading cause of years lived with disability worldwide …

Objective Using a patient‐informed regimen, we conducted an exploratory randomized,
double‐blind, placebo‐controlled study to systematically investigate the effects of psilocybin …

The fifth cranial nerve is the common denominator for many headaches and facial pain
pathologies currently known. Projecting from the trigeminal ganglion, in a bipolar manner, it …

Abstract Background and Purpose Cluster headache is a relatively rare, disabling primary
headache disorder with a major impact on patients' quality of life. This work presents …

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however,
many patients with migraine do not benefit from drugs that antagonize the CGRPergic …

Objective To report efficacy and safety of galcanezumab in adults with chronic cluster
headache. Background Galcanezumab is a humanized monoclonal antibody that binds to …

Cluster headache is a debilitating primary headache disorder that affects approximately
0.1% of the population worldwide. Cluster headache attacks involve severe unilateral pain …

The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …

Diseases in the central nervous system (CNS) are often difficult to treat. Antibody-and
protein-based therapeutics hold huge promises in CNS disease treatment. However …